Scott M. Whitcup - 17 Jun 2024 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Director
Signature
/s/ John Rakow, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
17 Jun 2024
Transactions value $
$0
Form type
4
Filing time
20 Jun 2024, 16:45:42 UTC
Previous filing
13 Jun 2023
Next filing
20 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +10.5K $0.00 10.5K 17 Jun 2024 Common Stock 10.5K $7.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option will vest and become exercisable on the earlier of June 17, 2025 or the 2025 annual meeting of stockholders, subject to (1) accelerated vesting upon a change of control and (2) the Reporting Person's continued service with the Issuer on the vesting date.